Positioned for Long-Term
We’re committed to the continued development of novel technology and we’re well-positioned to be the leader in veterinary regenerative medicine.
The process of taking a new veterinary drug from the idea stage through regulatory approval is rigorous. As we advance our pipeline of off-the-shelf therapies to bring the benefits of stem cell therapy to pets and their parents, we’ve got clinical trials in various stages of the approval process.
Feline Chronic Gingivostomatitis
Pivotal Study Phase
FCGS is a debilitating dental disease affecting about two million domestic cats, resulting in painful mucosal lesions. At Gallant, we’re nearing the finish line on approval for a product to help treat this disease. We're currently recruiting for additional participants. Visit the FCGS info page to learn more.
Feline Chronic Kidney Disease
Controlled Field Study Phase
Feline chronic kidney disease (CKD) is the number one killer of cats and has no direct interventional therapies on the market. Gallant’s cellular therapy is delivered intravenously (IV) and has shown promise in a feline model of CKD.
We’re not currently enrolling for this study, but we’re planning to launch the controlled study phase later this year, so stay tuned for updates.
More than 20% of all dogs, especially older dogs, get osteoarthritis (OA), which can result in pain and inflammation of one or more joints. Gallant’s cell therapy has demonstrated effectiveness and safety in a placebo-controlled clinical trial of cells administered into the joints of dogs.
Gallant is conducting a study, currently in the POC stage, to evaluate the effectiveness of GP-003 administered intravenously to dogs with OA. IV administration is the easier and preferred method of administration for cell therapies that do not require a specialist to perform difficult joint injections.
We’re not currently enrolling for this study, but stay tuned for updates. Our goal is to start the controlled study phase around mid-2024.
Canine Atopic Dermatitis
Canine atopic dermatitis is an allergic skin condition that affects more than 13 million dogs. Current therapies are administered either daily or monthly. Gallant’s cell therapy is designed to have a longer duration of action. Early pilot data in a placebo-controlled clinical trial suggest dogs may get a year or more of relief from a one-time therapy delivered intravenously.
Gallant completed the pilot study in 2022 and we're targeting a placebo-controlled large trial in 2025.
Like dogs, cats can also suffer from osteoarthritis. In fact, the problem is more prevalent in cats. Nearly 40% have clinical signs of OA, and 90% of cats over age 12 have radiographic evidence of the condition – nearly double that seen in dogs.
Gallant is working on a stem cell therapy solution to address this debilitating condition in cats.